Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT07208773

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of YL201 in Combination With Ivonescimab in Patients With Advanced Solid Tumors

Sponsor: Akesobio

Conditions Advanced Solid Tumors Non Small Cell Lung Cancer Small Cell Lung Cancer

Interventions Ivonescimab YL201

Updated 2 times since 2025 Last updated: Nov 14, 2025 Started: Oct 29, 2025 Primary completion: Jan 31, 2027 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Advanced Solid Tumors and Non Small Cell Lung Cancer, this trial is actively recruiting participants. The trial is conducted by Akesobio and has accumulated 2 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

2 versions recorded

Dec 2025 — Present [monthly]

Recruiting PHASE1/PHASE2

Status: Not Yet Recruiting → Recruiting
Nov 2025 — Dec 2025 [monthly]

Not Yet Recruiting PHASE1/PHASE2

First recorded

Oct 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Akesobio
MediLink Therapeutics (Suzhou) Co., Ltd.

Data source: MediLink Therapeutics (Suzhou) Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China